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Background. The TARDIS trial assessed the safety and efficacy of intensive versus guideline antiplatelet agents given for one month
in patientswith acute stroke or TIA.The aimof this substudywas to assess the effect of antiplatelet agents taken at baseline on platelet
function reactivity and activation. Methods. Platelet function, assessed by remotely measured surface expression of P-selectin,
was assessed in patients at their time of randomisation. Data are median fluorescence values. Results. The aspirin P-selectin test
demonstrated that platelet expression was lower in 494 patients taking aspirin than in 162 patients not: mean 210 (SD 188) versus
570 (435), difference 360.3 (95% CI 312.2–408.4) (2𝑝 < 0.001). Aspirin did not suppress P-selectin levels below 500 units in 23
(4.7%) patients. The clopidogrel test showed that platelet reactivity was lower in 97 patients taking clopidogrel than in 585 patients
not: 655 (296) versus 969 (315), difference 314.5 (95% CI 247.3–381.7) (2𝑝 < 0.001). Clopidogrel did not suppress P-selectin level
below 860 units in 24 (24.7%) patients. Conclusions. Aspirin and clopidogrel suppress stimulated platelet P-selectin, although one-
quarter of patients on clopidogrel have high on-treatment platelet reactivity. Platelet function testing may be performed remotely
in the context of a large multicentre trial. Trial registration ISRCTN47823388.
1. Introduction
Secondary prevention after ischaemic stroke (IS) or transient
ischaemic attack (TIA) comprises blood pressure and lipid
lowering and antithrombotic therapy, either anticoagulation
for atrial fibrillation (in 20% of patients) or antiplatelet ther-
apy for noncardioembolic stroke/TIA (in 80%) [1–6]. Anti-
platelets are effective at reducing recurrent events after IS or
TIA, as shown in multiple large trials and meta-analyses [7–
13], and UK guidelines recommend the following antiplatelet
regimes (in order): clopidogrel, combined aspirin and dipyri-
damole, aspirin alone, or dipyridamole alone [14, 15]. In
contrast to the use of blood pressure and lipid lowering
drugs and anticoagulants, where biomarkers (blood pressure,
blood lipids, and coagulation screen) can be used to adjust
treatment, antiplatelet drugs are given in a “fire and forget”
manner since there are no validated, widely available, or
inexpensive tests of platelet function that measure platelet
activity reliably and reproducibly, correlate with recurrent
events, and can be measured remotely from a dedicated
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platelet laboratory. As a result, antiplatelet therapy is given
routinely without knowledge of whether it is working in a
particular patient.
Unfortunately, a significant minority of patients (≥35%)
do not respond adequately to clopidogrel [16–25]; and a
similar but lesser problem exists for aspirin [16, 18, 20, 26,
27]. A number of laboratory-based systems for measuring
platelet function exist, including aggregation and commercial
systems such asMultiplate and VerifyNow [27–29]. However,
these approaches cannot be used remotely from the patient
(i.e., by general practitioners or at hospitals without specialist
equipment). Some of the point-of-care assays (PFA-100 and
VerifyNow) have shown very poor agreement [29, 30].
Surface platelet expression of P-selectin (CD62P,
PADGEM, Platelet Solutions Ltd.)may bemeasured remotely
in fixed blood [31] and correlates with other measures of
platelet function testing [32]. Using this approach, a small
study in 100 patients with acute coronary syndromes
(ACS) found that high on-treatment platelet reactivity with
clopidogrel was present in 42% of patients and that these had
an increased risk of subsequent cardiovascular death, acute
coronary syndrome, or stent thrombosis [33]. The present
study extends this work into patients with ischaemic stroke
or TIA and assessed ex vivo responsiveness to aspirin and
clopidogrel at baseline in patients recruited into the ongoing
TARDIS antiplatelet trial. The specific aim of the substudy
was to assess the effect of antiplatelet agents taken at baseline
on platelet reactivity assessed using measurements of platelet
surface P-selectin expression. We hypothesised that whilst
antiplatelet agents would suppress platelet surface P-selectin
expression in most patients, some would not exhibit such
suppression, especially when taking clopidogrel.
2. Methods
2.1. TARDIS. TARDIS assessed the safety and efficacy of
intensive versus guideline based antiplatelet therapy in
patients with acute ischaemic stroke or TIA [34, 35]. In brief,
TARDIS was an international parallel-group prospective
randomised open-label blinded-endpoint controlled trial
(trial registration ISRCTN47823388). Patients with acute
ischaemic stroke or TIA were randomised within 48 hours of
ictus to one month of open-label intensive antiplatelet
therapy—combined aspirin (300mg load and then 75mg
daily), clopidogrel (300mg load and then 75mg daily),
and dipyridamole (typically modified release 200mg twice
daily)—versus guideline antiplatelet therapy—combined
aspirin and dipyridamole, or clopidogrel alone (dosing as
above). Randomisation was made irrespective of what
antiplatelet therapy, if any, patients were taking prior to
enrolment. The primary outcome was stroke recurrence
and its severity at 90 days [34, 35]. Gastroprotection (with
either a protocol pump inhibitor or H2 antagonist) was
given according to local guidelines with the proviso that
omeprazole and esomeprazole should be avoided since
they may attenuate the effects of clopidogrel. The trial was
coordinated by a Trial Management Committee, overseen
by a Trial Steering Committee and International Advisory
Committee, and safety was monitored by an Independent
Data and Safety Monitoring Committee [34, 35].
The aim of this substudy was to assess the ex vivo effect
of antiplatelet agents taken at baseline on platelet activation.
Patients were grouped by antiplatelet agent(s) taken prior
to randomisation (as declared during collection of baseline
information), either regularly prior to stroke/TIA or given
in hospital after presentation and prior to enrolment into
TARDIS, that is, within 48 hours of their index event.
Information on antiplatelet agents was obtained through
history taking at the time of collecting baseline data and
not by review of prescription charts or general practice
records. Antiplatelet groups comprised aspirin alone, aspirin
and clopidogrel (a trial protocol violation [34]), aspirin and
dipyridamole, clopidogrel alone, and no antiplatelet prior
to randomisation. Groups were also combined into aspirin
versus no aspirin, and clopidogrel versus no clopidogrel.
Duration and dose of antiplatelet drugs are not presented in
view of the unreliable nature of this information when taken
by history at baseline.
2.2. P-Selectin Assay. A single blood biomarker assessing
platelet function—platelet surface P-selectin expression—
was used with measurements at baseline (i.e., prior to the
receipt of the randomised antiplatelet regimen) and at day
7 after randomisation. P-selectin is derived from alpha-
granules in resting platelets and becomes exposed on the
cell surface membrane upon platelet activation and granule
release. The level of P-selectin inside platelets is independent
of that produced by endothelial cells; this contrasts with
measurement of circulating soluble (plasma) P-selectin that
depends on both cell types and as reported previously in
stroke [36]. Platelet P-selectin expression was chosen since
blood can be taken and processed at multiple clinical sites
with measurement at a central core laboratory [31, 33]; no
other technique allows such remote assessment of platelet
function. Since TARDIS is still running, it was not possible
to lock the database and analyse on-treatment P-selectin
measurements; as a result, the following results relate only to
analyses using baseline prerandomisation P-selectin data.
Blood was taken by research staff who were trained in
venepuncture and sample preparation; samples were taken
immediately after randomisation in the Acute Stroke Unit.
Platelet surface P-selectin expression was measured using
commercial kits (Platelet Solutions Ltd. [PSL], Nottingham,
UK). Citrate anticoagulated blood was collected and kept at
37∘C (by a dry heat pad kept in an insulation pouch) prior
to incubation with platelet stimulants [31] comprising either
adenosine diphosphate (ADP) for testing clopidogrel (i.e.,
clopidogrel test) or arachidonic acid (AA) for testing aspirin
(i.e., aspirin test), both with added potentiating agents at low
concentration and EDTA to prevent aggregation; unstimu-
lated samples were also collected to provide information on
baseline expression. After 5 minutes of platelet stimulation,
fixing solution (PAMFix, PSL) was added [32]. Blood pro-
cessing was performed by the bedside to reduce time from
collection to stimulation. Fixed samples (which are stable for
at least 9 days [31]) were posted for flow cytometric analysis in
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the Nottingham flow cytometry laboratory, typically within 6
days of being taken.
Platelet reactivity was assessed as platelet surface P-
selectin expression as described previously [31]. In brief,
samples of fixed blood were incubated with fluorescent
antibodies to the platelet specific marker CD61 (used to
identify platelets) and CD62P (P-selectin). FACSflow was
added to samples immediately prior to analysis using a
flow cytometer (Becton Dickinson FACSCanto II). Median
Fluorescence (MF) of each sample (3000 platelets) was
recorded as a measure of platelet surface P-selectin expres-
sion. Data were then entered into the main TARDIS
database.
The platelet surface P-selectin expression assay has been
compared previously with optical and whole blood aggre-
gometry and aggregometry measurements agreed well with
data obtained in vitro and ex vivo following inhibition with
aspirin, cangrelor, or clopidogrel treatment [31, 37]. The
technique does not assess the effects of dipyridamole, in
contrast to some other approaches [38, 39].
2.3. Statistics. A subset of data from the TARDIS database
was extracted (patients with a P-selectin measurement and
without randomisation codes) to allow statistical analyses.
Results are given as number (%), median [interquartile
range], or mean (standard deviation, SD). “Bee swarm” plots
are used to present the distribution of ADP and AA related
P-selectin expression in subgroups. Cut points for ADP (500,
625, and 860 units [33]) and aspirin (400, 500 units) were
chosen prospectively and used to define responsiveness (level
lower than cut-off point) versus no response. The cut points
were chosen either because they have been used before
[33] or to provide guidance for future studies; in particular,
we will test these in analysis of the relationship between
randomised TARDIS treatment, P-selectin expression, and
clinical endpoints. Statistical analyses were performed using
SAS software (version 9.3).
3. Results
3.1. Patients. The trial started recruitment on April 7, 2009,
and data were extracted from the database on November
14, 2016, following recruitment of 3096 patients from 106
hospital sites in the UK. Of these, 689 (22.3%) patients
from 23 recruiting sites (21.7%) had a P-selectin expression
measurement at baseline; one patient was not included in
subsequent analyses having presented on triple antiplatelets
(𝑛 = 1, a protocol violation [34]). The characteristics of the
patients are shown in Table 1. The average age of patients was
68.6 years, 34.7%werewomen, and 75.0%were recruitedwith
an index event of ischaemic stroke.
The majority of patients (62.4%) had received aspirin
alone prior to randomisation; 16.1% patients had taken noth-
ing, and smaller numbers had taken clopidogrel alone (7.8%),
combined aspirin and dipyridamole (7.3%), or combined
aspirin and clopidogrel (6.1%) (Table 1). When assessed
as whether on aspirin or clopidogrel at baseline, 75.8% of
patients were taking aspirin and 13.9% clopidogrel. Gas-
troprotection was taken in 257 (37.3%) of patients in the
substudy, with most of these (237, 92.2%) receiving a proton
pump inhibitor.
3.2. P-Selectin in Response to Arachidonic Acid (Aspirin Test).
AA-stimulated platelet surface P-selectin expression was
lower in patients on aspirin than those who were not taking
it, mean difference in fluorescence 360.3 (95%CI 312.2, 408.4;
2𝑝 < 0.001) (Table 2). Using a cut-off point of 500MF, 23
(4.7%) patients on aspirin did not have suppressed P-selectin
expression in response to AA (Table 2). Acute aspirin admin-
istration was associated with a nonsignificant tendency to a
lower P-selectin expression in response to AA as compared
with chronic consumption (Table 3), perhaps reflecting that
acute administration of aspirin after stroke involves a loading
dose (300mg) rather than a daily maintenance dose of
75mg.
AA-stimulated P-selectin expression varied between
antiplatelet groups being lower in those patients taking
aspirin alone, combined aspirin and dipyridamole, or com-
bined aspirin and clopidogrel, as compared with clopidogrel
alone or no antiplatelets (Table 4, Figure 1). AA-stimulated
P-selectin was lower on aspirin than on combined aspirin
and clopidogrel, mean difference −98.2 (95%CI −183.7, −12.8;
2𝑝 = 0.025) (Table 4). There was no significant difference
in platelet surface P-selectin expression between patients on
aspirin alone as compared with those on combined aspirin
and dipyridamole, mean difference −58.3 (95% CI −140.2,
23.7; 2𝑝 = 0.16). Clopidogrel alone was associated with
higher AA-stimulated P-selectin expression than in patients
taking no antiplatelet agents (mean difference 183.6; 95% CI
50.0, 317.3; 2𝑝 = 0.0075).
3.3. P-Selectin in Response to ADP (Clopidogrel Test). ADP-
stimulated platelet surface P-selectin expression was lower
in patients on clopidogrel than those who were not taking
it, mean difference in fluorescence −314.5 (95% CI −381.7,
−247.3) (Table 2). Using a cut-off point of 860MF [33], 24
(24.7%) of patients taking clopidogrel did not have sup-
pressed P-selectin expression (Table 2). P-selectin expression
did not differ in patients who only received acute treatment
with clopidogrel as compared with those who had taken
clopidogrel prior to their stroke (Table 3).
ADP-stimulated P-selectin varied between groups receiv-
ing different antiplatelet agents being lower in the group of
patients taking clopidogrel versus aspirin-based therapy or no
antiplatelets (Table 4, Figure 2). ADP-stimulated P-selectin
was lower on clopidogrel than on combined aspirin and
clopidogrel, mean difference −180.6 (95% CI −298.3, −63.0;
𝑝 = 0.003) (Table 4). As expected, aspirin alone had no effect
on ADP-stimulated P-selectin expression in comparison with
patients taking no antiplatelets, mean difference −38.6 (95%
CI −104.5, 27.4; 2𝑝 = 0.25) (Table 4).
3.4. P-Selectin with No Stimulation. Platelet P-selectin ex-
pression did not vary by presence or absence of antiplatelets
prior to randomisation (Table 5, Figure 3).
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Beeswarm for AA MF, by antiplatelets
Antiplatelets before randomisation
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Figure 1: P-selectin in response to arachidonic acid (AA, aspirin test), by antiplatelet medication taken prior to randomisation. Data are
median fluorescence (MF). The horizontal lines show the median and interquartile values.
Beeswarm for ADP MF, by antiplatelets
Antiplatelets before randomisation
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Figure 2: P-selectin in response to adenosine diphosphate (ADP, clopidogrel test), by antiplatelet medication taken prior to randomisation.
Data are median fluorescence (MF). The horizontal lines show the median and interquartile values.
4. Discussion
Remote assessment of platelet function in patients with
acute stroke or TIA is feasible and reveals that aspirin
reduces AA-stimulated platelet surface P-selectin expression,
and clopidogrel lowers ADP-stimulated platelet P-selectin.
Using predefined cut-offs, whilst AA-stimulated P-selectin
was suppressed in 95% of patients in response to aspirin,
clopidogrel failed to reduce ADP-stimulated P-selectin in
24.7% of patients receiving the drug. The combination of
aspirin and clopidogrel was associated with higher AA and
ADP-stimulated P-selectin levels than either agent alone.
Whilst acute aspirin was associated with an insignificant
tendency to a lower AA-stimulated P-selectin than chronic
aspirin treatment, there was no difference in ADP-stimulated
P-selectin between acute and chronic clopidogrel consump-
tion. Unstimulated samples showed low levels of P-selectin
expression irrespective of whether antiplatelet agent had been
taken beforehand.
Remote assessment of platelet function is uniquewith this
assay system. Alternative approaches such as whole blood
aggregation, platelet rich plasma aggregation, Multiplate,
and VerifyNow require specific equipment that needs to
be proximal to patients and is usually found in specialist
platelet laboratories. The present system is comparable to
measurement of blood lipids or an international normalised
ratio: a blood sample is taken at, say, a clinic or general
practice, processed using a simple kit and sent (by post in
this study) to a core laboratory (not necessarily the one
used here) where it is analysed using flow cytometry, and a
result then returned for interpretation and conveyance to the
patient. This approach was feasible across multiple sites in
the UKwith the core laboratory in Nottingham.These results
suggest that response to aspirin and clopidogrel therapy can
be monitored remotely, much as they are for statins and oral
anticoagulants.
Attenuation of platelet expression of ADP- and AA-
stimulated P-selectin has been demonstrated previously for
clopidogrel and aspirin, respectively [31]. However, a signifi-
cant minority of patients (≥35%) do not respond adequately
to clopidogrel [16–25], and a similar but lesser problem
exists for aspirin [16, 18, 20, 26, 27]. Measurement of ADP-
stimulated P-selectin expression has been shown to iden-
tify individuals with acute coronary syndromes (ACS) who
have high on-treatment platelet reactivity with clopidogrel
[33]; these patients had an increased risk of subsequent
10 Stroke Research and Treatment
Beeswarm for Base MF, by antiplatelets
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Figure 3: P-selectin with no stimulation, by antiplatelet medication taken prior to randomisation. Data are median fluorescence (MF). The
horizontal lines show the median and interquartile values.
Table 4: P-selectin (median fluorescence) in response to ADP and arachidonic acid (AA), by antiplatelet medication taken prior to
randomisation, whether before or after stroke/TIA. Data are number (%) or mean (standard deviation). Comparisons by Chi-square test
or one-way analysis of variance.
All Aspirin Asp/Dip Asp/Clop† Clopidogrel None 2𝑝
AA
Number (%) 656 (21.2) 418 (20.5) 42 (25.6) 33 (15.3) 54 (34.2) 108 (21.1)
Mean (SD) 299 (312) 198 (172) 296 (269) 256 (227) 693 (381) 509 (448) <0.001
2𝑝, none versus — <0.001 0.002 0.005 <0.001 — —
<400 (%) 546 (83.2) 398 (95.2) 35 (83.3) 29 (87.9) 15 (27.8) 68 (63) <0.001
<500 (%) 557 (84.9) 404 (96.7) 37 (88.1) 29 (87.9) 16 (29.6) 70 (64.8) <0.001
ADP
Number (%) 682 (22) 424 (20.8) 42 (25.6) 50 (23.3) 54 (34.2) 110 (21.4)
Mean (SD) 925 (331) 944 (298) 758 (296) 1139 (388) 578 (276) 983 (316) <0.001
2𝑝, none versus — 0.54 0.10 <0.001 <0.001 — —
<860 (%) [33] 293 (43) 172 (40.6) 27 (64.3) 11 (22) 45 (83.3) 37 (33.6) <0.001
<625 (%) 125 (18.3) 55 (13) 15 (35.7) 6 (12) 34 (63) 14 (12.7) <0.001
<500 (%) 68 (10) 28 (6.6) 6 (14.3) 3 (6) 23 (42.6) 7 (6.4) <0.001
One patient on triple antiplatelet therapy (ADP 487 IU, AA 161 IU) and one patient on dipyridamole alone (ADP 1562 IU) (protocol violations) are excluded.
†Protocol violation [34].
cardiovascular death, acute coronary syndrome, or stent
thrombosis suggesting that the P-selectin measurement has
prognostic significance. Similarly, high on-treatment platelet
reactivity (alternatively called resistance) in patients taking
clopidogrel due to the presence of the CYP2C19 loss-of-
function allele is associated with a failure for this antiplatelet
to add to aspirin in preventing recurrence after minor stroke
and TIA [40]. A recent review summarises current data
on the magnitude of this problem [41]. Since the TARDIS
trial has not completed follow-up and data validation, it is
not possible currently to assess whether high on-treatment
platelet reactivity on clopidogrel is prognostic for recurrent
cerebrovascular events such as stroke and TIA; these data
will be analysed once the TARDIS main results have been
published.
A novel finding in this study was that the addition
of clopidogrel to aspirin was associated with higher AA-
stimulated P-selectin levels than aspirin alone, and the
addition of aspirin to clopidogrel was associated with higher
ADP-stimulated P-selectin levels than clopidogrel alone. A
nonsignificant tendency for the same phenomenon was seen
whereby higher AA-stimulated P-selectin levels were seen
in the presence of aspirin and dipyridamole as compared
to aspirin alone. These findings can be interpreted in three
ways. First, combining antiplatelets may interfere or reduce
the effect of each agent alone, a finding that has not been
previously reported. Whether such an effect might reduce
clinical effectiveness is unclear but this was not seen in the
European Stroke Prevention Study-2 (ESPS-2) which found
that combining aspirin and dipyridamole gave twice the
stroke preventative effect of either antiplatelet agent alone
when compared with placebo [9]. Second, differences in
doses of antiplatelets might explain these findings. Last, the
particular assay used here might detect apparent interference
when none is actually present, that is, a false positive finding.
Whatever the mechanism, the phenomenon of apparent
interference between antiplatelets requires further study.
The finding that acute aspirin administration is associated
Stroke Research and Treatment 11
Table 5: P-selectin (median fluorescence) with no stimulation, by antiplatelet medication taken prior to randomisation, whether before or
after stroke/TIA. Data are number (%) or mean (standard deviation). Comparisons by one-way analysis of variance.
All Aspirin Asp/Clop† Asp/Dip Clopidogrel None 2𝑝
Number (%) 685 (22.1) 426 (20.9) 42 (25.6) 50 (23.3) 54 (34.2) 111 (21.6)
Mean (SD) 93 (39) 91 (35) 88 (27) 104 (82) 90 (27) 98 (32) 0.069
with potentially lower P-selectin expression than chronic
administration supports the importance of loading patients
with aspirin after ischaemic stroke/TIA, as done in TARDIS.
The present study involved a large number of patients
with recent stroke or TIA, and they were taking a variety of
antiplatelet regimes, for varying periods of time (acute versus
chronic). Importantly the data come froma large high-fidelity
trial with prospective data collection [34, 35]. However, the
study has several caveats. First, only a minority (22.3%) of
patients from themain trial were recruited into this substudy,
and these differed in that they were more likely to be male
and have a history of previous ischaemic stroke. Nevertheless,
this should not have affected the ability of the study to detect
differences in P-selectin between patients taking different
antiplatelet agents. Further, the study was much larger than
earlier ones using the P-selectin assay [31, 33, 37]. Second,
the antiplatelet drug history came from the patient (or carer)
reflecting their memory of what had been taken recently, and
it was not possible to confirm this by direct measurement
of drugs or metabolites. Hence, patients may not have
been taking the drug(s) they said they were on, although
such noncompliance reflects real-world reality. Equally, some
patients reporting taking no antiplatelet drugsmay have been
taking aspirin; this is apparent in the proportion of patients
with low P-selectin levels on the aspirin test who reported
taking no antiplatelet drug and the presence of apparent
cross-over effects whereby the aspirin test gave low values
in patients on clopidogrel. There may be other causes of
low values in addition to antiplatelet therapy, potentially
including dietary sources of salicylate [42]. Third, this study
assessed platelet reactivity in a cross-sectional manner and
multiple assessments, as in longitudinal studies [39], might
be superior. Fourth, in the case of aspirin administration, a
mixed group of patients on acute and chronic antiplatelet
therapywere assessed, andpotential differences in antiplatelet
effect were seen; again, this reflects real-world reality. Fourth,
there is the possibility that low levels of platelet reactivity
could be due to prior platelet activation in the setting of
an acute event and reflect possible platelet exhaustion, a
possibility that would affect measurements performed using
a wide range of approaches to measurement of platelet
function, including platelet surface P-selectin expression.
Finally, patients would ideally have been rested prior to
venepuncture to avoid activity-related changes in platelet
function; unfortunately, it was not possible to mandate this
in the acute stroke unit/busy TIA clinic environment.
In summary, it is feasible to assess inhibition of platelet
function by quantifying P-selectin expression with the assay
kit used here in a central laboratory, remote from the site
of clinical assessment and venepuncture. P-selectin measures
are determined by antiplatelet therapy although a sizable
minority of patients on clopidogrel appear to be insensitive
to therapy. Assessment of the relationship between P-selectin
levels and subsequent clinical outcome will be assessed in a
further publication once the TARDIS trial was completed and
the data base locked, and data can be analysed taking account
of treatment assignment.
Additional Points
Recruiting Sites. Sites are number of patients with baseline
and/or on-treatment P-selectin measurement. The following
23 UK-based TARDIS sites took part in the P-selectin sub-
study: Ayr (2), Bath (14), Bury (4), Chester (12), Chesterfield
(11), Coventry (11), Derby (33), Durham (5), Exeter (11), Glas-
gowRoyal (9), Guildford (10), Ipswich (39), LondonCroydon
(1), London King’s College (103), London Princess Royal (13),
London St Bartholomew’s (24), London St George’s (164),
Mansfield (47), Nottingham (176), Preston (4), Stoke-on-
Trent (46), Upton (3), and Wolverhampton (7).
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